Paclitaxel poliglumex

Drug Profile

Paclitaxel poliglumex

Alternative Names: CHC 12103; CT-2103; Opaxio; PG - paclitaxel CTI BioPharma; PG-TXL; Poly(L-glutamic acid)-paclitaxel conjugate; Polyglutamate - Taxol; Polyglutamate-paclitaxel conjugate; Polyglutamic acid paclitaxel; PPX; Xyotax™

Latest Information Update: 11 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PG-TXL Company; University of Texas M. D. Anderson Cancer Center
  • Developer Brown University; CTI BioPharma; Gynecologic Oncology Group; National Cancer Institute (USA); State University of New York
  • Class Antineoplastics; Drug conjugates; Paclitaxels; Taxanes
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Glioblastoma; Glioma
  • Phase I/II Head and neck cancer
  • No development reported Non-small cell lung cancer; Oesophageal cancer
  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 05 May 2015 Phase-III is ongoing for Fallopiam tube cancer, ovarian cancer, peritoneal cancer; phase-II for glioblastoma/glioma; phase-I/II for head and neck cancer in USA
  • 30 May 2014 Cell Therapeutics is now called CTI BioPharma
  • 28 Jan 2014 The Gynecologic Oncology Group completes enrolment in the phase III GOG-0212 trial for Ovarian, Peritoneal or Fallopian tube cancer in USA (NCT00108745)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top